Medication Timeliness in Emergency Department in Pediatric Sickle Cell Disease Population Presenting with Vaso-Occlusive Episode

Derrick Goubeaux  
*Children's Mercy Hospital, dlgoubeaux@cmh.edu*

Kaitlyn Hoch  
*Children's Mercy Hospital, kmhoch@cmh.edu*

Gerald Woods  
*Children's Mercy Hospital, gwoods@cmh.edu*

Julie Routhieaux  
*Children's Mercy Hospital, jrouthieaux@cmh.edu*

Maureen Guignon  
*Children's Mercy Hospital, meguignon@cmh.edu*

Follow this and additional works at: [https://scholarlyexchange.childrensmercy.org/posters](https://scholarlyexchange.childrensmercy.org/posters)

---

**Recommended Citation**

[https://scholarlyexchange.childrensmercy.org/posters/53](https://scholarlyexchange.childrensmercy.org/posters/53)

This is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Posters by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Authors
Derrick Goubeaux, Kaitlyn Hoch, Gerald Woods, Julie Routhieaux, Maureen Guignon, and Valerie McDougall Kestner

This is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/posters/53
**Background**

Vaso-occlusive episode (VOE) is the most common acute complication for individuals with sickle cell disease (SCD) and the most common reason to seek medical care.

- **Recommendations** are rapid initiation of analgesia therapy upon arrival to emergency department (ED) with timely subsequent doses given as needed for pain.
  - At Children’s Mercy Hospital (CMH), recommendation is initial intranasal (IV) dose of analgesia within 60 minutes of registration and subsequent doses given every 20 minutes as needed for pain.
  - If patient is determined to need admission for further pain management, goal at CMH is to initiate continuous infusion (CI) of pain medication within 60 minutes of last bolus dose of pain.
  - At CMH, a delay in initiation of analgesia therapy upon arrival to ED as well as delay in initiation of CI of pain medication has been observed (Figure 1).
  - Delays in medication administration lead to poor pain control.

**Aim Statements**

By December 2018, reduce time to <60 minutes in patients with SCD presenting to ED with VOE for:

1. Time interval between registration and 1st dose of pain medication in 80% of patients.
2. Time interval between 1st and 3rd dose of pain medication in 80% of patients.
3. Time interval between 1st dose of medication and 3rd dose of pain medication in 60% of patients.

**Methods**

**Scope:** Pediatric patients with SCD presenting to the ED with VOE.

**Process Measure:** Utilization of intranasal fentanyl for initial pain medication option; adjust reassessment prompt follow bolus dose to every 20 minutes; consolidate initial ED pain plan (PP) and separate CI PP into single PP.

**Outcome Measure:** Percentage of patients meeting <60 minute time parameter for 1st dose of pain medication, 1st to 3rd dose of pain medication, and 3rd dose of pain medication to initiation of CI of pain medication.

**Balancing Measures:** Staff dissatisfaction with more rapid delivery of pain medications and initiation of CI in ED: patient/parent concern with effectiveness/comfort of intranasal pain medications.

**Results**

- Baseline data was obtained by retrospective chart review over a three month period, represented on Figures 2, 3, and 4.
  - A median of 58.8% of patients were receiving an initial dose of analgesia within 60 minutes of registration.
  - Sixty minutes between first and third dose occurred in 53.8% of patients.
  - Initiation of CI was occurring in 8.3% of patients within 60 minutes of the third dose of opioids.

- Over the first three PDSA cycles (June 2018 - August 2018), improvement has been noted across all 3 aims.
  - For the initial dosing, all 3 months were above baseline with one month reaching target at 80%.
  - For time between first and third dose of pain medication, 2 of 3 months were above baseline.
  - For time between third dose and initiation of CI, all 3 months were above baseline.

- Initial qualitative response from ED staff and nursing has been positive regarding initial countermeasures and care of the patients.

**Conclusions and Future Direction**

- Improved efficiency in time to initiation of analgesic support has been shown to lead to improved pain management in patients with SCD presenting to the ED for VOE.
  - It is anticipated that with the eventual achievement of the aims, a decreased admission rate will be noted.
  - For those individuals still requiring further analgesic support, it is felt faster initiation of CI will lead to quicker control of VOE and, subsequently, shorter hospitalizations.

- Integration of process measures into PP will allow for sustainable improvement/development of new standard.
  - Monitoring quantitative results will allow for identification of when PP not working.

- Additional countermeasures are currently being vetted in anticipation to adding to the current interventions to further improve the project’s efforts and maintain the long-term success of this project over time.
  - Plan will be to continue to run monthly PDSA cycles for a total of 6 months to evaluate response of timing to initial adjustments before integrating further interventions.

- At completion of a 12 month period of monthly data collection, data collection and review will then be done quarterly.
  - Presented at quarterly Hematology/Oncology/ED meeting.
  - Qualitative data will also be discussed to ensure continued improvement established by current project.